ALK+ ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation

Blood

Volumn 119, Issue 20, 2012, Pages 4698-4707

  Dejean, Emilie ^a   Foisseau, Marianne ^a   Lagarrigue, Fréderic ^b   Lamant, Laurence ^a,c   Prade, Naïs ^d   Marfak, Abdelghafour ^e   Delsol, Georges ^a   Giuriato, Sylvie ^a,c   Gaits Iacovoni, Fréderique ^b   Meggetto, Fabienne ^a,c  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b Université de Toulouse   (France)

^c European Research Initiative on Anaplasic Large Cell Lymphomas   (Austria)

^d CHU PURPAN   (France)

^e UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA ACTIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; GELATINASE B; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 2; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL INVASION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EPIDERMIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KERATINOCYTE; LARGE CELL LYMPHOMA; LEUKEMIA CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION;

EID: 84861214019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-386011     Document Type: Article

References (42)

1. Delsol G, Jaffe ES, Falini B, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow S, Campo E, Harris NL, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th Ed. Geneva, Switzerland: World Health Organization; 2008:312-316.
2. Mason DY, Harris NL, Delsol G, et al. Anaplastic large cell lymphoma (ALCL), ALK-negative. In: Swerdlow S, Campo E, Harris NL, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th Ed. Geneva, Switzerland: World Health Organization; 2008:317-319.
3. Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood. 1986;68(5): 1042-1049. (Pubitemid 17186379)
4. Lamant L, Pileri S, Sabattini E, Brugieres L, Jaffe ES, Delsol G. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica. 2010;95(3):449-455.
5. Savan R, McFarland AP, Reynolds DA, et al. A novel role for IL-22R1 as a driver of inflammation. Blood. 2011;117(2):575-584.
6. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002;62(5):1559-1566. (Pubitemid 34407823)
7. Rust R, Visser L, van der Leij J, et al. High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. Br J Haematol. 2005;131(5):596-608. (Pubitemid 43899625)
8. Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001;116(2):319-329. (Pubitemid 32173738)
9. Ferrero E, Fabbri M, Poggi A, Galati G, Bernasconi S, Zocchi MR. Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the alpha1 integrin I-domain. Eur J Immunol. 1998;28(8):2530-2536. (Pubitemid 28362727)
10. Bianchi MEDAMPs PAM. Ps and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81(1):1-5.
11. Meyer A, Staratschek-Jox A, Springwald A, et al. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma. 2008;49(6):1184-1189. (Pubitemid 351943266)
12. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72(11):1622-1631. (Pubitemid 44666730)
13. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-388.
14. Abe K, Ikeda T, Wake K, Sato T, Sato T, Inoue H. Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through downregulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol. 2008;60(1):91-97.
15. Liu PL, Tsai JR, Hwang JJ, et al. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol. 2010;43(5):530-538.
16. Lagarrigue F, Dupuis-Coronas S, Ramel D, et al. Matrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasion. Cancer Res. 2010; 70(17):6978-6987.
17. Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci. 2007;120(pt 6): 921-928. (Pubitemid 46638507)
18. Rattenholl A, Steinhoff M. Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect. 2008;21(7):369-381.
19. Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135-1147.
20. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7): 2652-2660. (Pubitemid 36857626)
21. Miething C, Peschel C, Duyster J. Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options. Curr Drug Targets. 2006;7(10):1329-1334. (Pubitemid 44509696)
22. Giuriato S, Foisseau M, Dejean E, et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood. 2010;115(20):4061-4070.
23. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72(1):234-240.
24. Epstein AL, Kaplan HS. Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 1974;34(6): 1851-1872.
25. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106(3):761-771. (Pubitemid 18089976)
26. Lippert U, Zachmann K, Henz BM, Neumann C. Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2. Exp Dermatol. 2004;13(8): 520-525. (Pubitemid 39144553)
27. Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14(4):431-441. (Pubitemid 46617319)
28. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97(13):975-980. (Pubitemid 41430563)
29. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11(7):615-628.
30. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol. 2005; 78(1):1-8. (Pubitemid 40979937)
31. Branco-Madeira F, Lambrecht BN. High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol Med. 2010;2(6):193-195.
32. Zhu S, Li W, Ward MF, Sama AE, Wang H. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets. 2010;9(1):60-72.
33. Shi J, Luo Q, Chen F, Chen D, Xu G, Li H. Induction of IL-6 and IL-8 by house dust mite allergen Der p1 in cultured human nasal epithelial cells is associated with PAR/PI3K/NFkappaB signaling. ORL J Otorhinolaryngol Relat Spec. 2010;72(5): 256-265.
34. Jovanović M, Stefanoska I, Radojcic L, Vicovac L. Interleukin-8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP)2 and MMP9 and integrins alpha5 and beta1. Reproduction. 2010; 139(4):789-798.
35. Limana F, Esposito G, D'Arcangelo D, et al. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS One. 2011;6(6):e19845.
36. Ratzinger G, Stoitzner P, Ebner S, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol. 2002;168(9):4361-4371. (Pubitemid 34441336)
37. Thirumangalakudi L, Yin L, Rao HV, Grammas P. IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis. 2007;11(3):305-311. (Pubitemid 47094028)
38. Koch S, Kohl K, Klein E, von Bubnoff D, Bieber T. Skin homing of Langerhans cell precursors: adhesion, chemotaxis, and migration. J Allergy Clin Immunol. 2006;117(1):163-168. (Pubitemid 43017155)
39. Zeh HJ, 3rd Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother. 2005;28(1):1-9.
40. Meyer A, Eberle N, Bullerdiek J, Nolte I, Simon D. High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy. Vet Comp Oncol. 2010; 8(2):127-137.
41. Lamore SD, Cabello CM, Wondrak GT. HMGB1-directed drug discovery targeting cutaneous inflammatory dysregulation. Curr Drug Metab. 2010;11(3):250-265.
42. Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res. 2002;8(6):469-472.